Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease : a systematic review and meta-analysis

Show full item record



Permalink

http://hdl.handle.net/10138/346324

Citation

Peyrin-Biroulet , L , Arkkila , P , Armuzzi , A , Danese , S , Guardiola , J , Jahnsen , J , Lees , C , Louis , E , Lukas , M , Reinisch , W , Roblin , X , Jang , M , Byun , H G , Kim , D-H , Lee , S J & Atreya , R 2022 , ' Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease : a systematic review and meta-analysis ' , BMC Gastroenterology , vol. 22 , no. 1 , 291 . https://doi.org/10.1186/s12876-022-02347-1

Title: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease : a systematic review and meta-analysis
Author: Peyrin-Biroulet, Laurent; Arkkila, Perttu; Armuzzi, Alessandro; Danese, Silvio; Guardiola, Jordi; Jahnsen, Jorgen; Lees, Charles; Louis, Edouard; Lukas, Milan; Reinisch, Walter; Roblin, Xavier; Jang, Minyoung; Byun, Han Geul; Kim, Dong-Hyeon; Lee, Sung Jeong; Atreya, Raja
Contributor organization: HUS Abdominal Center
Department of Medicine
Clinicum
University of Helsinki
Gastroenterologian yksikkö
Date: 2022-06-08
Language: eng
Number of pages: 16
Belongs to series: BMC Gastroenterology
ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-022-02347-1
URI: http://hdl.handle.net/10138/346324
Abstract: Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. Results We identified six eligible Crohn's disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn's disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn's disease and clinical response and clinical remission for ulcerative colitis) during the induction phase, with non-overlapping 95% confidence intervals. In the maintenance phase, similar proportions of infliximab- or vedolizumab-treated patients achieved clinical response, clinical remission, or mucosal healing in both Crohn's disease and ulcerative colitis. For the safety outcomes, rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar in infliximab- and vedolizumab-treated patients in both diseases. The infection rate was higher in infliximab for Crohn's disease and higher in vedolizumab when treating patients with ulcerative colitis. There was no difference between the treatments in the proportions of patients who reported serious infections in both indications. Conclusions Indirect comparison of infliximab and vedolizumab trials in adult patients with moderate-to severe Crohn's disease or ulcerative colitis demonstrated that infliximab has better efficacy in the induction phase and comparable efficacy during the maintenance phase and overall safety profile compared to vedolizumab.
Subject: Biological therapy
Tumor Necrosis Factor-alpha
Antibodies
Monoclonal
IBD
Crohn's disease
Ulcerative colitis
POST HOC ANALYSIS
CROHNS-DISEASE
MAINTENANCE THERAPY
ULCERATIVE-COLITIS
INDUCTION THERAPY
ORIGINATOR INFLIXIMAB
CLINICAL REMISSION
NOR-SWITCH
ADALIMUMAB
CT-P13
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Comparative_efficacy_and_safety_of_infl...pdf 4.622Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record